LaForce C - Search Results

1

Influence of C-159T SNP of the CD14 gene promoter on lung function in smokers.

Zhou H, Alexis NE, Almond M, Donohue J, LaForce C, Bromberg PA, Peden DB. Zhou H, et al. Among authors: laforce c. Respir Med. 2009 Sep;103(9):1358-65. doi: 10.1016/j.rmed.2009.03.007. Epub 2009 Apr 10. Respir Med. 2009. PMID: 19361972 Free PMC article.

2

Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, Mansfield L, Barker P, Wu Y, Jison M, Goldman M; BISE Study Investigators. Ferguson GT, et al. Among authors: laforce c. Lancet Respir Med. 2017 Jul;5(7):568-576. doi: 10.1016/S2213-2600(17)30190-X. Epub 2017 May 22. Lancet Respir Med. 2017. PMID: 28545978 Clinical Trial.

3

Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function.

Meltzer EO, Kuna P, Nolte H, Nayak AS, Laforce C; P04073 Study Investigators. Meltzer EO, et al. Among authors: laforce c. Eur Respir J. 2012 Feb;39(2):279-89. doi: 10.1183/09031936.00020310. Epub 2011 Aug 4. Eur Respir J. 2012. PMID: 21828036 Free article. Clinical Trial.

4

Dose counter performance of mometasone furoate/formoterol inhalers in subjects with asthma or COPD.

Weinstein C, Staudinger H, Scott I, Amar NJ, LaForce C. Weinstein C, et al. Among authors: laforce c. Respir Med. 2011 Jul;105(7):979-88. doi: 10.1016/j.rmed.2011.01.013. Epub 2011 Mar 12. Respir Med. 2011. PMID: 21398104 Free article. Clinical Trial.

5

Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.

Laforce C, Aumann J, de Teresa Parreño L, Iqbal A, Young D, Owen R, Higgins M, Kramer B; INTEGRAL Study Investigators. Laforce C, et al. Pulm Pharmacol Ther. 2011 Feb;24(1):162-8. doi: 10.1016/j.pupt.2010.06.005. Epub 2010 Jul 7. Pulm Pharmacol Ther. 2011. PMID: 20619353 Clinical Trial.

6

Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma.

Beeh KM, LaForce C, Gahlemann M, Wenz A, Toorawa R, Fležar M. Beeh KM, et al. Among authors: laforce c. Respir Res. 2015 Jul 16;16(1):87. doi: 10.1186/s12931-015-0243-1. Respir Res. 2015. PMID: 26177937 Free PMC article. Clinical Trial.

7

Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler.

Bernstein DI, Berkowitz RB, Chervinsky P, Dvorin DJ, Finn AF, Gross GN, Karetzky M, Kemp JP, Laforce C, Lumry W, Mendelson LM, Nelson H, Pearlman D, Rachelefsky G, Ratner P, Repsher L, Segal AT, Selner JC, Settipane GA, Wanderer A, Cuss FM, Nolop KB, Harrison JE. Bernstein DI, et al. Among authors: laforce c. Respir Med. 1999 Sep;93(9):603-12. doi: 10.1016/s0954-6111(99)90099-9. Respir Med. 1999. PMID: 10542973 Free article. Clinical Trial.

8

A randomized, double-blind, parallel-group, multicenter, placebo-controlled study of the safety and efficacy of extended-release guaifenesin/pseudoephedrine hydrochloride for symptom relief as an adjunctive therapy to antibiotic treatment of acute respiratory infections.

LaForce C, Gentile DA, Skoner DP. LaForce C, et al. Postgrad Med. 2008 Jul;120(2):53-9. doi: 10.3810/pgm.2008.07.1791. Postgrad Med. 2008. PMID: 18654069 Clinical Trial.

9

Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study.

LaForce C, Alexander M, Deckelmann R, Fabbri LM, Aisanov Z, Cameron R, Owen R, Higgins M. LaForce C, et al. Allergy. 2008 Jan;63(1):103-11. doi: 10.1111/j.1398-9995.2007.01555.x. Allergy. 2008. PMID: 18053019 Clinical Trial.

10

Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, Smith SG, Martin N, Mayer B, Yancey SW, Sousa AR, Chan R, Hopkins C; SYNAPSE study investigators. Han JK, et al. Lancet Respir Med. 2021 Oct;9(10):1141-1153. doi: 10.1016/S2213-2600(21)00097-7. Epub 2021 Apr 16. Lancet Respir Med. 2021. PMID: 33872587

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

101 results

Search Page